[go: up one dir, main page]

ZA200900902B - Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecy L)-1,4-benzoquinone - Google Patents

Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecy L)-1,4-benzoquinone

Info

Publication number
ZA200900902B
ZA200900902B ZA200900902A ZA200900902A ZA200900902B ZA 200900902 B ZA200900902 B ZA 200900902B ZA 200900902 A ZA200900902 A ZA 200900902A ZA 200900902 A ZA200900902 A ZA 200900902A ZA 200900902 B ZA200900902 B ZA 200900902B
Authority
ZA
South Africa
Prior art keywords
hydroxydecy
benzoquinone
dimethoxy
methyl
transmucosal administration
Prior art date
Application number
ZA200900902A
Other languages
English (en)
Inventor
Judith Dubach-Powell
Rudolf Hausmann
Pierre Vankan
Original Assignee
Santhera Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santhera Pharmaceuticals Ag filed Critical Santhera Pharmaceuticals Ag
Publication of ZA200900902B publication Critical patent/ZA200900902B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200900902A 2006-08-14 2009-02-06 Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecy L)-1,4-benzoquinone ZA200900902B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06016935A EP1891946A1 (en) 2006-08-14 2006-08-14 Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone

Publications (1)

Publication Number Publication Date
ZA200900902B true ZA200900902B (en) 2010-07-28

Family

ID=37564291

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900902A ZA200900902B (en) 2006-08-14 2009-02-06 Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecy L)-1,4-benzoquinone

Country Status (19)

Country Link
US (1) US20090208425A1 (xx)
EP (2) EP1891946A1 (xx)
JP (2) JP5665167B2 (xx)
CN (1) CN101541317B (xx)
AU (1) AU2007286491B2 (xx)
BR (1) BRPI0715901A2 (xx)
CA (1) CA2660577C (xx)
CY (1) CY1117860T1 (xx)
ES (1) ES2574087T3 (xx)
HU (1) HUE029241T2 (xx)
IL (1) IL196745A (xx)
MX (1) MX2009001674A (xx)
NZ (1) NZ574422A (xx)
PL (1) PL2051706T3 (xx)
PT (1) PT2051706T (xx)
RU (1) RU2429830C2 (xx)
SI (1) SI2051706T1 (xx)
WO (1) WO2008019769A1 (xx)
ZA (1) ZA200900902B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE529104T1 (de) 2008-04-09 2011-11-15 Santhera Pharmaceuticals Ch Idebenon zur behandlung von durch muskuläre dystrophie vermittelten atemwegserkrankungen
EP2246048A1 (en) 2009-04-30 2010-11-03 Santhera Pharmaceuticals (Schweiz) AG Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
WO2012022468A2 (en) 2010-08-16 2012-02-23 Santhera Pharmaceuticals (Schweiz) Ag Benzoquinone derivatives as modulators of mitchondrial function
CN102091038B (zh) * 2011-01-20 2012-07-25 天津大学 艾地苯醌纳米脂质载体透皮吸收制剂及制备方法
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
EP2620141A1 (en) 2012-01-25 2013-07-31 Santhera Pharmaceuticals (Schweiz) AG Thin film drug delivery system for the transmucosal administration of a 1,4-benzoquinone derivative
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
US20150150790A1 (en) * 2013-12-04 2015-06-04 Jao Hung Biotechnology Co., Ltd. Transdermal enhancer
DE102017104277A1 (de) 2017-03-01 2018-09-06 Lts Lohmann Therapie-Systeme Ag Transmukosales Verabreichungssystem für Idebenon
EP4121023A1 (en) 2020-03-19 2023-01-25 Bemido SA Idebenone for the treatment of acute respiratory distress syndrome (ards) in patients diagnosed with a coronavirus infection
US20240269091A1 (en) 2021-06-07 2024-08-15 Katholieke Universiteit Leuven Idebenone in the treatment of drug resistant epilepsy
CN115944599A (zh) * 2023-01-17 2023-04-11 中国药科大学 一种艾地苯醌滴丸及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2503571B2 (ja) * 1988-02-26 1996-06-05 武田薬品工業株式会社 脳循環代謝改善剤
JPH07103018B2 (ja) * 1988-09-16 1995-11-08 武田薬品工業株式会社 精神分裂病治療剤
JP3069458B2 (ja) * 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
CA2252519A1 (en) * 1996-07-11 1998-01-22 Keisuke Hirai Use of idebenone and analogues against beta amyloid induced cytotoxicity
JPH11116470A (ja) * 1997-08-12 1999-04-27 Takeda Chem Ind Ltd イデベノン含有経皮投与製剤
EP1021204B1 (en) * 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
CA2272971C (en) * 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
EP1206943B1 (en) * 1999-08-26 2010-04-07 Takeda Pharmaceutical Company Limited Matrix adhering to nasal mucosa
JP2003026567A (ja) * 2001-05-10 2003-01-29 Kanegafuchi Chem Ind Co Ltd 補酵素ｑを有効成分とする粘膜投与用組成物
ATE328283T1 (de) * 2002-07-01 2006-06-15 Santhera Pharmaceuticals Ch Screeningverfahren und verbindungen zur behandlung von friedreich ataxia
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
EP1618881A1 (en) * 2004-07-20 2006-01-25 Santhera Pharmaceuticals (Schweiz) GmbH Use of non-glucocorticoid steroids for the treatment of muscular dystrophy
KR20070060950A (ko) * 2004-10-07 2007-06-13 가부시키가이샤 상기 경피·경점막 흡수 제제
CA2602290C (en) * 2005-03-21 2012-01-17 Santhera Pharmaceuticals (Schweiz) Ag Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies

Also Published As

Publication number Publication date
HUE029241T2 (en) 2017-02-28
IL196745A (en) 2016-10-31
EP2051706B1 (en) 2016-05-11
ES2574087T3 (es) 2016-06-14
CN101541317B (zh) 2015-04-15
AU2007286491A1 (en) 2008-02-21
US20090208425A1 (en) 2009-08-20
JP2013100319A (ja) 2013-05-23
IL196745A0 (en) 2009-11-18
AU2007286491B2 (en) 2010-06-24
CA2660577C (en) 2012-05-01
CA2660577A1 (en) 2008-02-21
EP2051706A1 (en) 2009-04-29
SI2051706T1 (sl) 2016-06-30
CN101541317A (zh) 2009-09-23
PT2051706T (pt) 2016-07-18
EP1891946A1 (en) 2008-02-27
MX2009001674A (es) 2009-02-25
BRPI0715901A2 (pt) 2013-08-06
WO2008019769A1 (en) 2008-02-21
RU2429830C2 (ru) 2011-09-27
JP5665167B2 (ja) 2015-02-04
CY1117860T1 (el) 2017-05-17
RU2009103638A (ru) 2010-09-27
PL2051706T3 (pl) 2016-11-30
NZ574422A (en) 2011-04-29
JP2010500384A (ja) 2010-01-07
JP5907901B2 (ja) 2016-04-26

Similar Documents

Publication Publication Date Title
ZA200900902B (en) Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecy L)-1,4-benzoquinone
IL198753A0 (en) Oral transmucosal nicotine dosage form
GB0508306D0 (en) Nicotine dosage forms
IL201973A0 (en) 3,3-spiroindolinone derivatives
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
DOP2007000080A (es) Piridin [3,4-b] pirazinonas
HK1111065A1 (en) Lipid encapsulation
PL2205562T3 (pl) Pochodne 1,1,1-trifluoro-2-hydroksy-3-fenylopropanu
IL196101A0 (en) C-phenyl 1-thioglucitol compound
HK1137990A1 (en) Thienyl-containing glycopyranosyl derivatives as antidiabetics
EP2014626A4 (en) SEMICONDUCTOR CERAMIC COMPOSITION
IL199014A0 (en) 4-hydroxy-2-oxo-2,3-dihydro-1,3-
IL176630A0 (en) Benzimidazole derivatives
IL184433A0 (en) 5-aminoindole derivatives
HK1122218A1 (en) Anticancer concomitant drug
IL193475A0 (en) Benzimidazole derivatives
IL197883A0 (en) Combination drug
TWI373136B (en) Multiple-transistor semiconductor structure
EP2074647A4 (en) FORMATION OF INTERCONNECTION HOLES IN SLICES
EP2022454A4 (en) WHEELCHAIR
IL196200A0 (en) Polymorphic form of fluoro-7-(2,2,2-trifluoroethoxy)phenoxathin-10,10-dioxide
EP2060563A4 (en) CYCLIC AMINOALKYLCARBOXAMIDE DERIVATIVE
PL2099765T3 (pl) 5-, 6- lub 7-podstawione pochodne 3-aryloizochinolinoaminy jako środki przeciwnowotworowe
IL202221A0 (en) Composition for transdermal or transmucosal administration
GB0702895D0 (en) Delta 9 tetrahydrocannabinol derivatives